A comparison of three commercially available assays for growth hormone (Pharmacia hGH RIA, IDS Gamma-BCT GH and Delfia 22 kDa hGH) were used to measure growth hormone (GH) secretion in 26 short children after pharmacological stimulation. The IDS Gamma-BCT assay was compared with Pharmacia assay in 15 provocative tests (13 children; n = 94). The Pharmacia assay showed a strong positive proportional bias and this was particularly marked at GH > 20 mUlL; the mean difference between the assays at GH< 10 mUlL was 12%.
SUMMARY. A comparison of three commercially available assays for growth hormone (Pharmacia hGH RIA, IDS Gamma-BCT GH and Delfia 22 kDa hGH) were used to measure growth hormone (GH) secretion in 26 short children after pharmacological stimulation. The IDS Gamma-BCT assay was compared with Pharmacia assay in 15 provocative tests (13 children; n = 94). The Pharmacia assay showed a strong positive proportional bias and this was particularly marked at GH > 20 mUlL; the mean difference between the assays at GH< 10 mUlL was 12%.
The IDS Gamma-BCT assay was also compared with the Delfia 22 kDa assay in 18 provocative tests (13 children; n = 1(0). Results from the IDS assay was higher throughout the range 0-90 mUlL with a mean difference of 11'4070 in the range 10-90 mUlL; the mean difference between the assays at GH < 10 mUlL was -39%.
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The diagnosis of growth hormone (GH) deficiency in children is made by the demonstration of reduced growth velocity supported by low concentrations of GH during either physiological tests of GH secretion e.g. sleep or exercise, or following pharmacological stimulation. The threshold for deficiency is arbitrary but a value of 15 mUlL is usually used. I The difficulty in establishing a cut-off value is complicated by pre-analytical factors altering GH secretiorr-? and analytical variation due to the use of different commercial assays."
Assay dependent variation in GH measurement has been recognized for many years and is related to problems with the choice of calibrants and standards and variation in antibody specificity.' In external quality assessment (QA) schemes material with values of approximately 5 and 20 mUlL are used as these are values at which clinical decisions are often made. We report on the comparison of GH measurement by three different commercial immuno-assays using samples with GH values of up to 80 mUlL obtained during pharmacological stimulation tests.
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METHODS
The three assays were immunometric: Pharmacia hGH RIA (Pharmacia, Milton Keynes), IDS Gamma-BCT GH (lmmuno Diagnostic Systems, Tyne & Wear) and Delfia 22 kDa hGH (Wallac (UK), Milton Keynes). The Pharmacia hGH assay is an immunoradiometric method (IRMA) employing polyclonal rabbit-sheep antibodies with 125 1 as signal and Sepharose particles as a solid phase. The IDS Gamma-BCT GH assay employs polyclonal sheep-monoclonal antibodies with 125 1 as signal and the capture antibodies are bound to the tube. The Delfia 22 kDa hGH assay uses two murine monoclonal antibodies with europium as a signal. All assays were performed according to the manufacturers' protocols. All serum samples were stored at -20°C prior to analysis.
Specimens were initially analysed soon after they were collectedfor clinicalpurposes and subsequently in batches by the second method i.e, in one series specimens were analysed by Pharmacia first and Omnia Gamma-BCT second and in the second series by Omnia Gamma-BCT first and Delfia second. Inter-and intra-assay coefficients of variation (CY) were < IOlI7o (Table 1) . Assay linearity was established by serial dilution of plasma samples from acromegalic subjects using the appropriate diluent for each assay. All three assays were linear to at least 80 mUlL. The assays were compared by the Altman & Bland method of ditferences."
PATIENTS
Thirty-three provocative tests were performed on 26 short children (median age 10 years, range 2-18) using arginine (7 studies), clonidine (5) and glucagon (21).
The protocols used were: O·5 glkg of arginine i.v, over 30 min, 0·15 mg/rn? clonidine orally and 15/Lg/kg of glucagon i.rn .. Blood samples were taken at 30 min intervals for 120 min (arginine), 150 min (clonidine) and 180 min (glucagon). All tests were performed after an overnight fast.
RESULTS
The IDS Gamma-BCT assay was compared with Pharmacia assay in 94 samples from 15 provocative tests in 13 children. The Pharmacia assay showed a strongly positive proportional bias and this was particularly marked at GH > 20 mUlL (Fig. 1) . For mean values of GH< 10 mUlL (Pharmacia-IDS), the mean difference between the assays was 12%. The mean difference at GH 10-20 mUlL was 2·7mU/L (1'0-3'8,95 percentiles).
The IDS Gamma-BCT assay was also compared with the Delfia 22 kDa assay in 100 samples from 18 provocative tests (13 children). Results from the IDS assay was higher throughout the range 0-90 mUlL and the mean difference was 11·4% in the range 10-90 mUlL (Fig. 2) . For mean values of GH < 10 mUlL, the mean difference between the assays was -39%. The mean difference at GH 10-20 mUlL was 4·9 mUlL (3' 0-6' 7, 95 percentiles).
DISCUSSION
This comparison of three commercially available immunometric assays for GH has shown that the development of immunometric assays has not removed the inaccuracies of the early immunoassays for GH. Unfortunately sample volumes were too small to assay all samples by all three methods. However, it is clear from this study that there is a systematic bias between the Pharmacia and the IDS Gamma-BCT and probably with the Delfia 22 kDa assay. The largest differences between IDS and Pharmacia assays (> 15 mUlL) occurred during the provocation tests and may be due to variations in the proportions of each of the GH isoforms released under the pharmacological conditions. The absolute discrepancy was greatest at high peak values of GH which are clearly not important in the context of the diagnosis of GH deficiency. The diagnosis of GH deficiency is now largely made on auxological studies and resting and stimulated GH concentrations values are used as supportive evidence. However, some physicians use the peak value obtained after pharmacological stimulation with a cut-off of approximately 15 mU/L. 1 Our data show that the mean differences between the three assays at GH value 1O-20mU/L were 2·7 and 4·9mU/L. These differences may be sufficient to sway a clinical diagnosis and the decision to treat with GH.
The small and even positive bias between the IDS Gamma-BCT and Delfia assays is consistent with the recognition of the predominant 22 kDa form by the latter. However, the explanation for the strongly positive bias by the Pharmacia which was highest after stimulation is more obscure. It is most likely to be due to recognition of dimers, oligorners and other variants of GH. There is normally a persistence of the 20 kDa isoform after stimulation due to delayed clearance;' but differential recognition of this isoform cannot explain the difference between assays as shown by a recent NEQAS experiment. Serum spiked with pure 20 kDa GH (IS 801505) demonstrated no difference between the IDS Gamma-BCT and Pharmacia assays (NEQAS (UK), personal communication 1993). Curiously, it appears that after stimulation there is a greater release of bio-active rather than immunoreactive GH 7 but this could not explain the difference between the assays. A further contribution to the difference between assays is the higher analytical variance shown by the Pharmacia assay at high GH concentrations.
The overall differences between the assays in this report were up to 1751170 of the mean value (for GH 0-20 mUlL) showing that performance of the assay has not improved since the external QA reports from either the UK in 1988 8 or
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Germany in 1991. 9 A comparison of 10 different assays using pooled samples from subjects undergoing 24 h sampling showed variation between I· 8 and 5·9 nglmL or 330%.10 The differences in all these reports can only be explained on the basis of different antibody specificity.
In conclusion, the use of GH measurements in the diagnosis of growth hormone deficiency is still extremely method-dependent. The choice of assay must be made after studying its relationship to growth data and to date this appears only to have been performed with the Hybritech hGH IRMA.II
